Attached files

file filename
EX-32.2 - EX-32.2 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex322_9.htm
EX-31.2 - EX-31.2 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex312_6.htm
EX-31.1 - EX-31.1 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex311_10.htm
EX-23.1 - EX-23.1 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex231_8.htm
EX-10.47 - EX-10.47 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex1047_186.htm
EX-10.35 - EX-10.35 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex1035_684.htm
EX-10.34 - EX-10.34 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex1034_685.htm
EX-10.33 - EX-10.33 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex1033_686.htm
EX-4.12 - EX-4.12 - HTG MOLECULAR DIAGNOSTICS, INChtgm-ex412_807.htm
10-K - 10-K - HTG MOLECULAR DIAGNOSTICS, INChtgm-10k_20191231.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of HTG Molecular Diagnostics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:   March 25, 2020

 

By:

/s/ John L. Lubniewski

 

 

 

John L. Lubniewski

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)